This is a working overview of prohibited list, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-28 and is reviewed periodically as new material appears.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or flake |
| Solubility class | Soluble in water and aqueous buffer | Also soluble in some polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Typical analytical method | LC-MS/MS | Reversed-phase separation with mass detection |
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
42 BC to at least early 5th century, Mark Antony (emblem: capricorn) Legio V Macedonica (Macedonian): 43 BC – AD 637, Octavian (emblem: bull) Legio V Alaudae (Larks): 52 BC – AD 70 or 86 (destroyed either during the Batavian rebellion or by the Dacians in first Battle of Tapae), Julius Caesar (emblem: elephant) Legio VI Ferrata (Ironclad): 52 BC – after AD 250, Julius Caesar (emblem: bull, she-wolf and Romulus and Remus); twin legion of Legio VI Victrix Legio VI Victrix (Victorious): 41 BC – after AD 402, Octavian (emblem: bull) Legio VII Claudia Pia Fidelis (loyal and faithful to Claudius): before 58 BC – 44 BC, Julius Caesar; disbanded and re-formed by Octavian Legio VIII Augusta: 59 BC – 46 BC, Julius Caesar, originally named Gallica, disbanded and re-enlisted by Octavian as Legio VIII Augusta, 44 BC – AD 420 Legio IX Hispana (Hispanian): before 58 BC – AD 120-161 Legio X Equestris (Equestrian): before 58 BC – 45 BC, Julius Caesar's personal legion, later renamed as Legio X Gemina Legio X Fretensis (of the sea strait): levied by Octavian in 41/40 BC, recorded to have existed at least until the 410s Legio XI Claudia: 58 BC – 45 BC, Julius Caesar (emblem: Neptune), disbanded, reconstituted by Octavian Legio XII Fulminata (Thunderbolt): 57 BC – AD 45, Julius Caesar, first reconstituted by Lepidus in 43 BC, named by Mark Antony as Legio XII Antiqua (Ancient) Legio XIII Gemina (Twin): 57 BC – 45 BC: Julius Caesar, later (41 BC) reconstituted by Octavian. The legion that crossed the Rubicon with Caesar on his assault on Rome.
When rock climbing, it is not safe to grab ledges or crevices without examining them first, as snakes are cold-blooded and often sunbathe atop rock ledges. In the United States, more than 40 percent of people bitten by snakes intentionally put themselves in harm's way by attempting to capture wild snakes or by carelessly handling their dangerous pets—40 percent of that number had a blood alcohol level of 0.1 percent or more. It is also important to avoid snakes that appear to be dead, as some species will roll over on their backs and stick out their tongue to fool potential threats. A snake's detached head can immediately act by reflex and potentially bite. The induced bite can be just as severe as that of a live snake. As a dead snake is incapable of regulating the venom injected, a bite from a dead snake can often contain large amounts of venom. Snakebite-proof gaiters can also be worn to help prevent snakebites. As many snakes have relatively small fangs, gaiters may provide a physical barrier that prevents the fangs from penetrating the skin of the lower legs.
=== Police corruption accusation === In 2007, a representative of Innocence en Danger, a global NGO launched in 1999 to combat pedophilia, at the time with international offices in Germany, France and the United States, said that "the corrupt police [of Portugal] don't care" about the problem, and cited as an example the cases of Mendonça and Madeleine McCann. After three years, the NGO gave up trying to open an office in Portugal, saying that they were pressured by local authorities.
A probable diagnosis is based on the history of the illness and cognitive testing, with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal brain aging. Examination of brain tissue is the only way to definitively diagnose Alzheimer's, but neuroimaging techniques and fluid biomarkers have made it possible to diagnose probable Alzheimer's disease in vivo. No known treatments can stop or reverse its progression, though some may temporarily improve symptoms. A healthy diet, physical activity, and social engagement are generally beneficial in aging, and may help in reducing the risk of cognitive decline and Alzheimer's. Affected people become increasingly reliant on others for assistance, often placing a burden on caregivers. The pressures can include social, psychological, physical, and economic elements. Exercise programs may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioral problems or psychosis due to dementia are sometimes treated with antipsychotics, but this has an increased risk of early death. As of 2020, there were approximately 50 million people worldwide with Alzheimer's disease. It most often begins in people over 65 years of age, although up to 10% of cases are early-onset impacting those in their 30s to mid-60s. It affects about 6% of people 65 years and older, and women more often than men. The disease is named after German psychiatrist and pathologist Alois Alzheimer, who first described it in 1906.
Sources: en.wikipedia.org
Loose connective tissue, also known as areolar tissue, is a cellular connective tissue with thin and relatively sparse collagen fibers. They have a semi-fluid matrix with lesser proportions of fibers. Its ground substance occupies more volume than the fibers do. It has a viscous to gel-like consistency and plays an important role in the diffusion of oxygen and nutrients from the capillaries that course through this connective tissue as well as in the diffusion of carbon dioxide and metabolic wastes back to the vessels. Moreover, loose connective tissue is primarily located beneath the epithelia that cover the body surfaces and line the internal surfaces of the body. It is also associated with the epithelium of glands and surrounds the smallest blood vessels. This tissue is thus the initial site where pathogenic agents, such as bacteria that have breached an epithelial surface, are challenged and destroyed by cells of the immune system. In the past, the designations areolar tissue, adipose tissue, and reticular tissue have been listed as subsets of loose connective tissue. However, they are no longer considered subsets of loose connective tissue. Loose connective tissue is a subset of connective tissue proper. Furthermore, areolar tissue is the same as loose connective tissue, adipose tissue is a subset of specialized connective tissue, and reticular tissue is the presence of reticular fibers and reticular cells together forming the stroma of hemopoietic tissue (specifically the red bone marrow) and lymphatic tissue organs (lymph nodes and spleen but not the thymus).
transactinides Also superheavy elements. In the periodic table, the set of chemical elements with an atomic number greater than 103, i.e. those heavier than the actinides. The transactinides are a subset of the transuranic elements.
== Spectroscopy == Both the fluorescence excitation and emission spectrums of wild-type EosFP are shifted ~65 nm to the right upon excitation toward the red end of the spectrum. This spectral change is caused by an extension of the chromophore accompanied by a break in the peptide backbone between Phe-61 and His-62 in an irreversible mechanism. The presence of a crisp isosbestic point at 432 nm also suggests an interconversion between two species. An absorption peak at 280 nm is visible due to aromatic amino acids which transfer their excitation energy to the green chromophore. The quantum yield of the green-emitting form of Eos is 0.7. In the red shifted species, there are pronounced vibronic sidebands separate from the main peak at 533 nm and 629 nm in the excitation spectrum and emission spectrum respectively. There is another peak in the red excitation spectrum at 502 nm likely due to FRET excitation of the red fluorophore. The quantum yield of the red-emitting form is 0.55. EosFPs variants show almost no difference in spectroscopic properties, therefore, it is likely that the structural modifications which arise from separation of interfaces have little to no effect on the structure of the fluorophore-binding site.
Sources: en.wikipedia.org
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.
No. Lyophilisation slows degradation rather than stopping it, and the rate depends on residual moisture, temperature and light exposure. Freezer storage extends useful life but does not make the material permanent.
A certificate is only as good as its traceability to a specific batch and a named laboratory. Documents lacking batch numbers, method descriptions or laboratory identifiers carry little weight. Confirming what was actually received generally requires a separate test of the material in hand.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.